Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
Table 2
Demographic and tumor characteristics of the ER/PR/HER2 subtypes in women with invasive breast cancer from the California Cancer Registry 2000–2010†.
ER+/PR+/HER2− 80,765 (57.3%)
ER+/PR+/HER2+ 13,719 (9.6%)
ER+/PR−/HER2− 13,887 (9.7%)
ER+/PR−/HER2+ 4,735 (3.3%)
ER−/PR+/HER2− 1,148 (0.8%)
ER−/PR+/HER2+ 563 (0.4%)
ER−/PR−/HER2− 18,724 (13.1%)
ER−/PR−/HER2+ 9,792 (6.8%)
Total 143,333
Mean age at diagnosis(±SD)
AJCC Stage at diagnosis
Stage 1
41,004 (64.3%)
5,252 (8.2%)
6,423 (10.1%)
1,634 (2.6%)
466 (0.7%)
172 (0.3%)
6,043 (9.5%)
2,759 (4.3%)
63,753 (45.7%)
Stage 2
28,398 (52.8%)
5,493 (10.2%)
4,842 (9.0%)
1,919 (3.6%)
458 (0.9%)
252 (0.5%)
8,473 (15.8%)
3,911 (7.3%)
53,746 (38.6%)
Stage 3
7,125 (44.2%)
1,825 (11.3%)
1,549 (9.6%)
685 (4.2%)
131 (0.8%)
95 (0.6%)
2,746 (17.0%)
1,982 (12.3%)
16,138 (11.6%)
Stage 4
2,325 (40.7%)
685 (12.0%)
675 (11.8%)
341 (6.0%)
50 (0.9%)
29 (0.5%)
876 (15.3%)
733 (12.8%)
5,714 (4.1%)
Age at diagnosis
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
<40
4,369 (41.1%)
1,561 (14.7%)
669 (6.3%)
391 (3.7%)
140 (1.3%)
99 (0.9%)
2,305 (21.7%)
1,104 (10.4%)
10,638 (7.4%)
40–49
14,592 (55.4%)
3,238 (12.3%)
1,516 (5.8%)
759 (2.9%)
329 (1.2%)
147 (0.6%)
3,823 (14.5%)
1,940 (7.4%)
26,344 (18.4%)
50–59
20,061 (53.8%)
3,530 (9.5%)
3,583 (9.6%)
1,433 (3.8%)
290 (0.8%)
150 (0.4%)
5,188 (13.9%)
3,068 (8.2%)
37,303 (26.0%)
60–69
19,206 (58.9%)
2,696 (8.3%)
3,633 (11.1%)
1,084 (3.3%)
194 (0.6%)
85 (0.3%)
3,729 (11.4%)
1,997 (6.1%)
32,624 (22.8%)
70–79
14,487 (61.7%)
1,792 (7.6%)
2,816 (12.0%)
681 (2.9%)
126 (0.5%)
55 (0.2%)
2,369 (10.1%)
1,140 (4.9%)
23,466 (16.4%)
80–89
7,239 (62.8%)
800 (6.9%)
1,477 (12.8%)
339 (2.9%)
60 (0.5%)
21 (0.2%)
1,131 (9.8%)
461 (4.0%)
11,528 (8.0%)
90+
811 (56.7%)
102 (7.1%)
193 (13.5%)
48 (3.4%)
9 (0.6%)
6 (0.4%)
179 (12.5%)
82 (5.7%)
1,430 (1.0%)
Race/ethnicity
White
56,245 (59.5%)
8,455 (8.9%)
9,546 (10.1%)
2,972 (3.1%)
705 (0.7%)
306 (0.3%)
10,801 (11.4%)
5,443 (5.8%)
94,473 (66.3%)
Black
3,557 (41.7%)
811 (9.5%)
859 (10.1%)
302 (3.5%)
88 (1.0%)
48 (0.6%)
2,165 (25.4%)
690 (8.1%)
8,520 (6.0%)
Hispanic
11,693 (50.2%)
2,489 (10.7%)
2,046 (8.8%)
823 (3.5%)
222 (1.0%)
142 (0.6%)
3,830 (16.4%)
2,048 (8.8%)
23,293 (16.3%)
Asian/Pacific Islander
8,496 (54.1%)
1,834 (11.7%)
1,304 (8.3%)
597 (3.8%)
124 (0.8%)
67 (0.4%)
1,767 (11.2%)
1,520 (9.7%)
15,709 (11.0%)
American Indian
268 (52.9%)
55 (10.8%)
49 (9.7%)
23 (4.5%)
4 (0.8%)
0 (0.0%)
74 (14.6%)
34 (6.7%)
507 (0.4%)
Socioeconomic status (SES)
SES 1—Low
7,990 (49.5%)
1,776 (11.0%)
1,451 (9.0%)
572 (3.5%)
154 (1.0%)
87 (0.5%)
2,676 (16.6%)
1,420 (8.8%)
16,126 (11.4%)
SES 2
12,185 (53.1%)
2,255 (9.8%)
2,192 (9.5%)
802 (3.5%)
179 (0.8%)
99 (0.4%)
3,427 (14.9%)
1,816 (7.9%)
22,955 (16.2%)
SES 3
16,200 (55.9%)
2,763 (9.5%)
2,820 (9.7%)
984 (3.4%)
230 (0.8%)
130 (0.4%)
3,887 (13.4%)
1,991 (6.9%)
29,005 (20.5%)
SES 4
19,392 (57.4%)
3,166 (9.4%)
3,404 (10.1%)
1,098 (3.2%)
254 (0.8%)
117 (0.3%)
4,208 (12.5%)
2,150 (6.4%)
33,789 (23.9%)
SES 5—high
23,792 (60.3%)
3,585 (9.1%)
3,825 (9.7%)
1,219 (3.1%)
317 (0.8%)
126 (0.3%)
4,288 (10.9%)
2,309 (5.9%)
39,461 (27.9%)
Tumor grade
Well differentiated; Grade I (low)
23,904 (79.4%)
1,708 (5.7%)
3,344 (11.1%)
331 (1.1%)
117 (0.4%)
16 (0.1%)
508 (1.7%)
159 (0.5%)
30,087 (22.1%)
Moderately differentiated; Grade II (low)
38,340 (67.0%)
5,803 (10.1%)
5,765 (10.1%)
1,789 (3.1%)
308 (0.5%)
143 (0.3%)
3,045 (5.3%)
2,002 (3.5%)
57,195 (42.1%)
Poorly differentiated; Grade III (high)
13,891 (30.0%)
5,285 (11.4%)
3,694 (8.0%)
2,223 (4.8%)
637 (1.4%)
345 (0.7%)
13,643 (29.4%)
6,640 (14.3%)
46,358 (34.1%)
Undifferentiated; Grade IV (high)
584 (25.9%)
256 (11.4%)
175 (7.8%)
108 (4.8%)
30 (1.3%)
29 (1.3%)
697 (30.9%)
374 (16.6%)
2,253 (1.7%)
Tumor category
T1a and microscopic
5,336 (58.7%)
787 (8.7%)
1,025 (11.3%)
337 (3.7%)
68 (0.7%)
42 (0.5%)
691 (7.6%)
806 (8.9%)
9,092 (6.6%)
T1b
15,628 (68.3%)
1,653 (7.2%)
2,402 (10.5%)
516 (2.3%)
146 (0.6%)
46 (0.2%)
1,702 (7.4%)
797 (3.5%)
22,890 (16.6%)
T1c
31,526 (61.7%)
4,801 (9.4%)
4,695 (9.2%)
1,467 (2.9%)
375 (0.7%)
163 (0.3%)
5,615 (11.0%)
2,472 (4.8%)
51,114 (37.1%)
T2
20,782 (49.0%)
4,512 (10.6%)
3,901 (9.2%)
1,620 (3.8%)
392 (0.9%)
204 (0.5%)
7,484 (17.7%)
3,495 (8.2%)
42,390 (30.7%)
T3
5,313 (42.9%)
1,303 (10.5%)
1,268 (10.2%)
539 (4.4%)
106 (0.9%)
59 (0.5%)
2,368 (19.1%)
1,423 (11.5%)
12,379 (9.0%)
Total cases with ER/PR/HER2; some variables have fewer cases due to missing data. †Percentages are of total cases within a demographic or tumor variable.
